CCM
AERI

Copernicus Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Copernicus Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-78,132
Closed -$4.67M – 24
2017
Q4 		$4.67M Buy
+78,132
New +$4.74M 3.48% 14

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Copernicus Capital Management's AERI Position: Q1 2018 in Review

Copernicus Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 78,132 shares — an estimated $4.67M sold.

Copernicus Capital Management first reported a position in AERI in Q4 2017 and held it in 1 quarter. The position peaked at $4.67M in Q4 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • Copernicus Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Copernicus Capital Management sold 78,132 Aerie Pharmaceuticals shares in Q1 2018, an estimated $4.67M.
  • Copernicus Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Copernicus Capital Management's Aerie Pharmaceuticals position peaked at $4.67M in Q4 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Copernicus Capital Management's 13F filing for Q1 2018, filed 1 May 2018.